Government Shutdown 2025: What to know on air travel, social security, student loans, SNAP, military and more

The federal government has initiated a shutdown due to a lapse in funding, resulting in unpaid federal workers, imminent layoffs, and significant operational curtailments across various agencies. While critical services such as air traffic control and Social Security payments persist, the FDA has halted new drug approvals and long-term food safety initiatives, and HHS has furloughed thousands and frozen research grants. A prolonged shutdown threatens essential programs like WIC and could lead to broader economic deceleration through reduced consumer spending and increased regulatory uncertainty, particularly affecting industries reliant on government oversight and funding.

Analysis

The US federal government shutdown introduces significant operational and financial uncertainty across multiple sectors, characterized by a strongly negative sentiment. The most acute impact is on the healthcare and biotech industries, as the Food and Drug Administration (FDA) has ceased processing new drug and medical device applications, creating a critical regulatory bottleneck. Furthermore, the freeze on new research grants from the National Institutes of Health (NIH) and the furloughing of over 32,000 Health and Human Services (HHS) workers will disrupt the R&D pipeline for both public and private entities. On a macroeconomic level, the non-payment of federal workers and the threat of "imminent" layoffs will directly curtail consumer spending, while potential disruptions to nutritional programs like WIC could amplify this effect. Although essential services such as air traffic control and Social Security payments are maintained, the halt in new controller training and safety inspections poses a medium-term risk to aviation efficiency and safety. The political framing of the shutdown as an "opportunity" for permanent agency cuts suggests a high probability of a prolonged event, elevating the risk premium for industries dependent on government spending and regulatory clarity.

Key Decisions for Investors

• Investors should immediately review exposure to biotech and pharmaceutical companies with near-term regulatory catalysts, as the halt in new FDA application reviews will likely delay approvals and negatively impact valuations.
• Consider reducing exposure to consumer discretionary stocks and REITs with high concentrations in regions heavily reliant on federal employment, as the cessation of pay and threat of layoffs will directly impact local economies.
• While defense operations are continuing, the delayed payments to civilian and military personnel introduce headline risk and potential cash flow disruptions for government contractors, warranting increased scrutiny of this sector.
• The heightened political uncertainty points toward a defensive portfolio posture, as a prolonged shutdown could erode broader economic growth and increase market volatility.